Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11671854 | 0.94 | TSHR (0.46) | CYP2A6ALDH1A1ADRA2AADRA2BADRA2C | |
| SCHEMBL13618783 | 0.84 | CYP2A6 (0.46) | CYP2A6ALDH1A1LOXL2KDM4EGAA | |
| SCHEMBL12991122 | 0.83 | MAOA (0.49) | ALDH1A1KDM4EGAAMEN1MAPT | |
| SCHEMBL12733256 | 0.83 | CYP2A6 (0.47) | CYP2A6ALDH1A1LOXL2MAPTHPGD | |
| SCHEMBL30239355 | 0.83 | DRD2 (0.44) | CYP2A6ALDH1A1LOXL2KDM4EGAA | |
| SCHEMBL9174261 | 0.81 | CYP2A6 (0.43) | CYP2A6ALDH1A1LOXL2KDM4EGAA | |
| SCHEMBL10330355 | 0.81 | ADRA2A (0.58) | CYP2A6ALDH1A1ADRA2AADRA2BADRA2C | |
| SCHEMBL23573064 | 0.80 | CYP2A6 (0.52) | CYP2A6ALDH1A1LOXL2KDM4EGAA | |
| SCHEMBL63804 | 0.80 | ALDH1A1 (0.52) | CYP2A6ALDH1A1LOXL2KDM4EGAA | |
| SCHEMBL12806211 | 0.79 | HRH3 (0.44) | CYP2A6ALDH1A1LOXL2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431186-A | Preparation method of N-alkylamino substituted benzonitrile compound | 江苏省农药研究所股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-118290303-A | Process for preparing N-methyl-N-substituted-4-cyanoaniline compound | 江苏省农药研究所股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018113624-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | 深圳微芯生物科技有限责任公司 | 2018-06-28 | — | — | WO | disclosed |
| US-9295673-B2 | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150320727-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC | 2015-11-12 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150158859-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150105385-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012116237-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-08-30 | — | — | WO | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-7851074-B2 | Organic electroluminescent display device and chemical compounds for liquid crystals | TOHOKU PIONEER CORPORATION (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | WYETH (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | WYETH (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | WYETH (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009120826-A1 | 2-ARYL- AND 2-HETEROARYLTHIAZOLYL COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | WYETH (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090058277-A1 | Organic Electroluminescent Display Device and Chemical Compounds for Liquid Crystals | TOHOKU PIONEER CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-4011173-A | MODIFIED NEMATIC MIXTURES WITH POSITIVE DIELECTRIC ANISOTROPY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105385-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CYP2A6 2986/4885ALDH1A1 3154/4885ADRA2A 2968/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CYP2A6 2986/4885ALDH1A1 3154/4885ADRA2A 2968/4885 |
| US-20150158859-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CYP2A6 2417/4885ALDH1A1 2379/4885ADRA2A 3869/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | CYP2A6 4823/4885ALDH1A1 3450/4885ADRA2A 3346/4885 |
| US-20150087627-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, PIK3CA, AKT1 | CYP2A6 4533/4885ALDH1A1 4423/4885ADRA2A 4168/4885 |
| US-20150320727-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CYP2A6 2417/4885ALDH1A1 2379/4885ADRA2A 3869/4885 |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | SEC63, SEC62, SEC22B | CYP2A6 1608/4885ALDH1A1 2705/4885ADRA2A 4434/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | CYP2A6 4607/4885ALDH1A1 4563/4885ADRA2A 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.